Business Standard

Gland Pharma slips 10%, hits 52-week low on disappointing Q1 results

Q1 profit after tax tumbled 35 per cent YoY and 20 per cent QoQ to Rs 229 crore, due to lower operational income

Gland Pharma

Deepak Korgaonkar Mumbai
Shares of Gland Pharma hit a 52-week low of Rs 2,232 as they slipped 10 per cent on the BSE in Thursday's intra-day trade. The company reported 35 per cent year-on-year (YoY) decline in profit after tax (PAT) to Rs 229 crore in June quarter (Q1FY23), due to lower operational income. The pharmaceutical company's PAT stood at Rs 351 crore in Q1FY22. On a sequential basis, PAT was down 20 per cent from Rs 286 crore in Q4FY22.

The stock has fallen below its previous low of Rs 2,421.30, touched on July 14, 2022. In the past three months,

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 21 2022 | 9:53 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to